通过左心室喷射小部分谱结合循环和 thiazide 利尿剂: CLOROTIC 试验
Marta Sánchez-Marteles1, Vanesa Garcés-Horna1, José Luís Morales-Rull2
1Internal Medicine Department, Hospital Clínico Universitario "Lozano Blesa," Calle de San Juan Bosco, Zaragoza, Spain; Aragon Health Research Institute (IIS Aragon), Zaragoza, Spain.
JACC. Heart failure
|June 27, 2024
概括
在急性心力衰竭 (AHF) 中,添加化 (HCTZ) 于化可以改善利尿反应,而不考虑左心室喷射分数 (LVEF). 这种组合疗法对AHF患者有效且安全.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在CLOROTIC试验中,在急性心力衰竭 (AHF) 患者中,增加化 (HCTZ) 添加到furosemide后,改善了利尿反应.
- 这项研究调查了这些好处是否在不同水平的左心室喷射率 (LVEF) 上有所不同.
研究的目的:
- 为了评估添加HCTZ添加到furosemide在AHF患者的有效性,由LVEF分层.
- 为了确定LVEF是否会影响联合利尿剂治疗的治疗效果.
主要方法:
- 一个随机,双盲,安慰剂控制的CLOROTIC试验的后期分析,涉及230名AHF患者.
- 患者接受了静脉注射的罗西米德与HCTZ或安慰剂,评估了LVEF对结果的影响.
主要成果:
- 与安慰剂相比,添加HCTZ到furosemide显著改善了利尿反应,包括体重减轻和24小时利尿症.
- 在LVEF类别 (截止点在40%和50%) 或LVEF作为连续变量之间没有观察到治疗效果的显著差异.
- 安全终点,包括死亡率,再入院和不良事件,在LVEF组之间是相似的.
结论:
- 将HCTZ添加到静脉注射的罗胺是增强AHF尿液反应的有效策略.
- 基线LVEF似乎不会改变在AHF患者中将HCTZ与furosemide结合的治疗效果.
更多相关视频
相关概念视频
Heart Failure Drugs: Diuretics
362
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
362
Antihypertensive Drugs: Thiazide-Class Diuretics
595
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
595
Antihypertensive Drugs: Potassium-Sparing Diuretics
511
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
511
Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
Antihypertensive Drugs: Action of Diuretics
665
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
665
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419


